BioArctic (BIOA-B.ST) Stock Analysis & AI Equity Report
BioArctic (BIOA-B.ST) overview
BioArctic (BIOA-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, BioArctic reported revenue of SEK 257m and operating profit of SEK -229m; the year-end share price was 199.50 SEK and market capitalisation was SEK 17,664m. BioArctic is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioArctic's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focused on treatments for neurodegenerative diseases. It develops antibody-based drug candidates for Alzheimer’s disease, Parkinson’s disease and ALS, and its BrainTransporter technology helps deliver medicines across the blood-brain barrier. Value is driven by royalties, partnerships, and license agreements, including Leqembi with Eisai.
Generate the BioArctic report
BioArctic is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioArctic and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.